Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

NCT04891770 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: Tenofovir Alafenamide
DRUG: VIR-2218
DRUG: Nivolumab
DRUG: Selgantolimod

Sponsor

Gilead Sciences

Collaborators

[object Object]